SCLX

Scilex Holding Company · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Other
Website cilexholding.com
Employees(FY) 109
ISIN US80880W1062

Performance

-13.07%

-31.27%

-56.55%

-75.55%

-78.06%

YTD

-65.58%

Profile

Scilex Holding Company, a biopharmaceutical company, focuses on acquiring, developing, and commercializing non-opioid management products for the treatment of acute and chronic pain. It offers ZTlido, a prescription lidocaine topical product for the relief of neuropathic pain related with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also develops SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trial for the treatment of low back pain; and SP-104 (4.5 mg), a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Advanced Technical Analysis

Technical Analysis of SCLX 2024-12-20

The stock's Moving Average Score of 10 indicates a strong bearish sentiment, while the Oscillators Score of 46 suggests a neutral stance. Overall, the combined Technical Score of 28 reinforces a bearish outlook, signaling potential challenges for upward price movement in the near term.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SCLX

Stock Rank

Recent News & Updates

2024-12-15 20:00
Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation(Globenewswire)
2024-12-12 23:23
Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering(Globenewswire)
2024-12-11 19:21
Scilex Holding Company Announces $17 Million Registered Direct Offering(Globenewswire)
2024-12-10 23:49
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025(Globenewswire)
2024-12-10 18:30
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trial(Globenewswire)
2024-12-09 19:00
NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes Colla(Globenewswire)
2024-12-09 18:00
Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and Neuro(Globenewswire)
2024-11-21 17:00
Scilex Holding Company Announces Receipt of Notice from Nasdaq(Globenewswire)
2024-11-14 20:00
Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 19, 2024(Globenewswire)
2024-11-11 04:01
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination(Yahoo Finance)
2024-11-05 23:24
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously(Globenewswire)
2024-10-29 18:00
Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (L(Globenewswire)
2024-10-28 18:00
Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock(Globenewswire)
2024-10-27 18:00
Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary(Globenewswire)
2024-10-15 19:00
Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securiti(Globenewswire)
2024-10-15 16:00
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur a(Globenewswire)
2024-10-08 01:58
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024(Globenewswire)
2024-10-07 23:50
Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing(Globenewswire)
2024-10-06 22:00
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt(Prnewswire)
2024-10-06 21:52
Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile(Globenewswire)
2024-09-25 21:00
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025(Globenewswire)
2024-09-17 21:00
Scilex Holding Company Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex's Commercial Products and the Satisfaction of FSF 33433 LLC $10 Million Loan(Globenewswire)
2024-09-11 21:00
Scilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy (NABP )(Globenewswire)
2024-09-08 21:00
Scilex Holding Company to Present at the 26th Annual H.C. Wainwright Global Investment Conference(Globenewswire)
2024-09-04 21:00
Scilex Holding Company Announces Acceptance of Presentation at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 19, 2024(Globenewswire)
2024-09-02 21:00
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination(Globenewswire)
2024-09-02 21:00
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value (Globenewswire)
2024-08-29 21:00
Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024(Globenewswire)
2024-08-28 21:00
Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA Label(Globenewswire)
2024-08-20 21:00
Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB Patent Related to the Treatment of Acute Pain(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.